{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:35:04Z","timestamp":1790789704605,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UAB Radiation Oncology Department Pilot Grant","award":["Pilot Grant"],"award-info":[{"award-number":["Pilot Grant"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric brainstem tumor with a 5-year survival of &lt;1%. Up to 80% of the DIPG tumors contain a specific K27M mutation in one of the two genes encoding histone H3 (H3K27M). Furthermore, p53 mutations found in &gt;70\u201380% of H3K27M DIPG, and mutant p53 status is associated with a decreased response to radiation treatment and worse overall prognosis. Recent evidence indicates that H3K27M mutation disrupts tri-methylation at H3K27 leading to aberrant gene expression. Jumonji family histone demethylases collaborates with H3K27 mutation in DIPG by erasing H3K27 trimethylation and thus contributing to derepression of genes involved in tumorigenesis. Since the first line of treatment for pediatric DIPG is fractionated radiation, we investigated the effects of Jumonji demethylase inhibition with GSK-J4, and mutant p53 targeting\/oxidative stress induction with APR-246, on radio-sensitization of human H3K27M DIPG cells. Both APR-246 and GSK-J4 displayed growth inhibitory effects as single agents in H3K27M DIPG cells. Furthermore, both of these agents elicited mild radiosensitizing effects in human DIPG cells (sensitizer enhancement ratios (SERs) of 1.12 and 1.35, respectively; p &lt; 0.05). Strikingly, a combination of APR-246 and GSK-J4 displayed a significant enhancement of radiosensitization, with SER of 1.50 (p &lt; 0.05) at sub-micro-molar concentrations of the drugs (0.5 \u03bcM). The molecular mechanism of the observed radiosensitization appears to involve DNA damage repair deficiency triggered by APR-246\/GSK-J4, leading to the induction of apoptotic cell death. Thus, a therapeutic approach of combined targeting of mutant p53, oxidative stress induction, and Jumonji demethylase inhibition with radiation in DIPG warrants further investigation.<\/jats:p>","DOI":"10.3390\/ijms21020490","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"490","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG"],"prefix":"10.3390","volume":"21","author":[{"given":"Anatoly","family":"Nikolaev","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Fiveash","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-2638","authenticated-orcid":false,"given":"Eddy S.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/1570159X14666160509123229","article-title":"Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets","volume":"15","author":"Johung","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fonc.2012.00205","article-title":"Diffuse intrinsic pontine glioma: Poised for progress","volume":"2","author":"Warren","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3171\/2012.11.PEDS12317","article-title":"Management and outcome of focal low-grade brainstem tumors in pediatric patients: The St. Jude experience","volume":"11","author":"Klimo","year":"2013","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00247-009-1368-5","article-title":"Conventional MRI at presentation does not predict clinical response to radiation therapy in children with diffuse pontine glioma","volume":"39","author":"Liu","year":"2009","journal-title":"Pediatr. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/neuonc\/nos330","article-title":"A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method","volume":"15","author":"Walker","year":"2013","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3171\/2008.11.PEDS08281","article-title":"Treatment of diffuse intrinsic brainstem gliomas: Failed approaches and future strategies","volume":"3","author":"Frazier","year":"2009","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bjc.6600552","article-title":"Treatment of paediatric pontine glioma with oral trophosphamide and etoposide","volume":"87","author":"Wolff","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pbc.21154","article-title":"Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children\u2019s Oncology Group phase II study","volume":"50","author":"Korones","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2002.04.109","article-title":"Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children\u2019s Cancer Group","volume":"20","author":"Jennings","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0360-3016(98)00501-X","article-title":"There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy","volume":"43","author":"Mandell","year":"1999","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijrobp.2012.04.006","article-title":"Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: A matched-cohort analysis","volume":"85","author":"Janssens","year":"2013","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2014.01.013","article-title":"Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): A randomized controlled trial","volume":"111","author":"Zaghloul","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_14","first-page":"147","article-title":"Pathology, Molecular Genetics and Epigenetics of Diffuse Intrinsic Pontine Glioma","volume":"30","author":"Buczkowicz","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.3716","article-title":"Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma","volume":"20","author":"Hashizume","year":"2014","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood-2018-99-119990","article-title":"Phase 1b\/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"ref_20","unstructured":"Aprea Therapeutics (2019). Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS) [News Release], Aprea Therapeutics. Available online: https:\/\/bit.ly\/2IsKSKa."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc2716","article-title":"Tumour suppression by p53: A role for the DNA damage response?","volume":"9","author":"Meek","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"jcs215525","DOI":"10.1242\/jcs.215525","article-title":"Histone H3K27 methylation modulates the dynamics of FANCD2 on chromatin to facilitate NHEJ and genome stability","volume":"131","author":"Zhang","year":"2018","journal-title":"J. Cell Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-16-0352","article-title":"Combining Chk1\/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma","volume":"16","author":"Zeng","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1158\/1078-0432.CCR-19-0126","article-title":"TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)","volume":"15","author":"Werbrouck","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","article-title":"Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma","volume":"15","author":"Katagi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_26","first-page":"79298","article-title":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma","volume":"12","author":"Chi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality","volume":"13","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_28","first-page":"1","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: A case report","volume":"5","author":"Hall","year":"2019","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1200\/JCO.2019.37.15_suppl.10046","article-title":"ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma","volume":"2019","author":"Gardner","year":"2019","journal-title":"JCO"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/490\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:19:35Z","timestamp":1760361575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijms21020490"],"URL":"https:\/\/doi.org\/10.3390\/ijms21020490","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201912.0076.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}